***Available online at*** **www.scholarsresearchlibrary.com**

**Scholars Research Library**

**Der Pharmacia Lettre, 2022, 14(7): 01-05**
***(http://scholarsresearchlibrary.com/archive.html)***

**ISSN 0975-5071**
**USA CODEN: DPLEB4**

# *In Vitro* Anticancer Evaluation of Cisplatin Nanoparticles Encompass Natural Polymer

**Bhavani J*, Ravichandran S**

*Department of Pharmaceutical Science, PSV College of Pharmaceutical Science And Research, Tamil Nadu, India*

***Corresponding author:** Bhavani J, Department of Pharmaceutical Science, PSV College of Pharmaceutical Science And Research, Tamil Nadu, India, E-mail: tnbhavanisundaram@gmail.com*

***Received:** 31-Aug-2020, Manuscript No. DPL-20-18419; **Editor assigned:** 03-Sep-2020, Pre QC No. DPL-20-18419 (PQ); **Reviewed:** 17-Sep-2020, QCNo.DPL-20-18419; **Revised:** 06-Sep-2022, QI NO. DPL-20-18419, Manuscript No. DPL-20-18419 (R); **Published:** 04-Oct-2022,DOI: 10.37532/ dpl.2022.14.25.*

## ABSTRACT

Our research work has been indicated cisplatin nanoparticles encompass natural polymer using natural as a polymer formulated for the enhanced anti-cancer activity. Nano precipitation method has been selected for the preparation of cisplatin comprising natural Gumghatti as polymer. Prepared nanoparticles have exposed the average particle size, polydispersity index and zeta potential of 143.4 nm, 0.16 and 28.5 mV respectively. Further the encapsulation efficiency, percentage drug loading and percentage yield for all the formulations were substantial, especially for the trial 6 the values observed were 93.56, 83.55 and 76.54 respectively. The *in vitro* release of cisplatin Gumghatti nano formulations and were determined by dissolution tester by USP apparatus II in 900 ml phosphate buffer pH 6.8. The dissolution media were maintained at 37°C ± 0.5°C with a paddle rotation speed at 50 rpm. The amount of drug used was equivalent to 15 mg at specified time intervals (5, 10 15, 20, 25 30 60, 90 and 120 minutes) The results shows that prepared nanoparticles having 98.53% of drug release in 120 minutes, further it indicates more than 95% of drug release in 2 hours. *In vitro* anticancer activity has been performed using cell lines the results indicated that the enhanced anticancer activity of the prepared nano formulation.

**Keywords:** Cisplatin, Gumghatti, Nano formulations, *In vitro*, Cell lines, Anticancer activity.

## INTRODUCTION

The patients receiving chemotherapy has considerably increased. Growth of reliable and novel formulations to treat the patients became necessary [1-5]. From the detection of new entity to patients administration for facing difficulty, as the pharmaceutical fields are concerned with the novel formulation of drugs with increased efficacy. Cisplatin is amid the best and broadly used antineoplastic medications. Also, it is likewise a strong anti-cancer specialist and the most regularly employed medication as a part of Blood and Marrow Transplantation (BMT). It was at first combined to specifically target growth cells, despite the fact that the speculated system of tumor specificity (enactment by disease cell phosphamidases) happened to be unessential to its action. In any case, cisplatin novel digestion system and inactivation by aldehyde

dehydrogenase is in charge of its unmistakable cytotoxic properties. Differential cell articulation of aldehyde dehydrogenase affects the anticancer remedial file and anti cancer properties of cisplatin. The novel formulation cisplatin has been prepared for better antitumor activity cisplatin is an alkylating agent with cytotoxic and anticancer activities. The parent compound is inactive *in vitro* and exerts its biologic activity through metabolites, mainly phosphoramide mustard generated by hepatic microsomal enzymes. The exact mode of cytotoxic and anticancer action of Cisplatin at cellular level is not completely understood. Myelosuppression, hemorrhagic cystitis, alopecia and gonadal damage are the main toxic effects. The contemporary research proposes that nanotechnologies may prompt the advancement of novel malignancy treatment. This is very promising approach of developing a nanoformulation with the novel polymer Gumghatti with the drug cisplatin.

Essential bone malignancies begin in the bone in which the growth at first structures in the cells of the bone; these can be separated sign is starts of tumours, cause disease while optional disease starts somewhere else in the body and spreads deep down. Cases of essential bone growth include osteosarcoma, Ewing sarcoma, Fibrous histiocytoma and Chondrosarcoma. It is one of the most widely recognized kinds of bone disease. It is frequently creates in youngsters and youthful grown-ups-Ewing sarcoma, as a rule, forms in the pelvis, or thigh bone. Ninety percentages of patients build up this sort of growth when they are less than 20 years old. Chondrosarcoma, for the most part, creates in grownups. It begins in the ligament cells and proceeds onward to the bone. The patient at first encounters torment in the influenced zone. After some period, the agony deteriorates. Sometimes the misery is inconspicuous and the patient may not see a specialist for a while. The movement of suffering amid Ewing sarcoma has a tendency to be speedier than in most other bone malignancies. Regularly, bone malignancies torment is profound, pestering and has changeless character. Swelling in the influenced range, the danger of crack, weight accidentally, bump in the affected territory playing out a trunk radiograph is the initial step to analyse lung tumour. This may uncover an undeniable mass, extending of mediastinum, atelectasis and pneumonia-imaging commonly used towards given data about sort and degrees disease. Bronchoscopy/guided biopsy regularly utilized test the tumour for histopathology. Lung disease usually shows up the lone aspiratory knob on a trunk radiograph. Tumour screening utilizes therapeutic tests to recognize illness in vast gatherings of individuals who have no manifestations. Registered CT screens could identify growth and give man alternatives to react way delays life. This type of screening describes the possibility of death from lung growth flat out measure of zero point three per cent. These are quickest developing sorts of osteosarcoma. At the end, when above under a magnifying instrument, they don't look like typical bone and have numerous cells during the time spent separating into new cells. Most osteosarcomas that happen in youngsters and teenagers are Osteoblastic, Chondroblastic, Fibroblastic and Telangiectasia. These tumours fall in the middle of high-review and poor quality osteosarcomas. Quality osteosarcomas have slowest developing osteosarcomas.

## MATERIALS AND METHODS

### *Preparation of gumghatti cisplatin nanoparticles*

Cisplatin and gumghatti was purchased from sigma Aldrich. All the reagents and solvents used were analytical grade and standard. Formulation of cisplatin gumghatti nanoparticles. Cisplatin was mixed with water to prepare solution and add (DMSO) as cosolvent to make the inner phase more homogeneous. Then 150 mg of gum ghatti was dissolved in acetone and the solution was added to the drug to form dispersion. The dispersion was add to 10 ml of aqueous ethanol solution (70%) after 5 minutes of mixing, the organic solvent was removed by evaporation at 38°C under normal pressure, nanoparticles were separated by using cooling centrifuge at 10000 rpm for 20 min supernatant was removed and nanoparticles was washed with water and dried at room temperature in a desicator [ 6-13].

### *Encapsulation efficiency of cisplatin gumghatti*

Nanoparticles encapsulation efficiency, which is the percentage of the actual amount of drug encapsulated in the polymeric carrier relative to the total amount of drug taken for Nanoparticles preparation, is calculate by using the following equation;

%Encapsulation efficiency=(Actual drug loading/Theoretical drug loading) × 100

To calculate actual drug loading an accurately weighed quantity of cisplatin was sonicate in 10 ml of methanol for 5 minutes and filter through 0.45 µl syringe filter. Cisplatin concentration is analyzed by measuring the absorbance at 287 nm using UV is spectrophotometer [14-17].

***Dissolution study***

The dissolution profiles of cisplatin gumghatti Nano formulations and were determined in a dissolution tester by USP apparatus II in 900 ml phosphate buffer pH 6.8. The dissolution media were maintained at 37°C ± 0.5°C with a paddle rotation speed at 50 rpm. The amount of drug used was equivalent to 15 mg. At specified time intervals (5, 10 15, 20, 25 30 60, 90 and 120 minutes.) 5 ml of dissolution media were withdrawn and replaced with an equal volume of the fresh medium at 37°C to maintain a constant total volume. Samples were filtered through a 0.22 µm nylon membrane filter and assayed for drug content spectrophotometrically at 363 nm using UV1700, Shimadzu Corporation, Japan UV/V is double beam spectrophotometer after appropriate dilution with phosphate buffer pH 6.8. Cumulative percentage of drug dissolved in the preparations was calculated using calibration equations. Dissolution tests were performed in three vessels per formulation (n=3) [18-23].

***MTT assay***

The MTT assay, based on the conversion of the yellow tetrazolium salt-MTT, to purple-formazan crystals by metabolically active cells, provides a quantitative determination of viable cells. Cells will be plated on to 96 well plates at a cell density of $2 \times 105\ mL^{-1}$ per well in 100 µL of RPMI 1640 and allowed to grow in $CO_2$ incubator for 24 h (37°C, 5% $CO_2$). The medium will be removed and replaced by fresh medium containing different concentrations of sample for 48 h. The cells will incubated for 24 h to 48 h (37°C, 5% $CO_2$). Then, 20 µL MTT ([3- (4, 5-dimethylthiazol-yl)-2, 5- diphenyltetrazolium bromide]) stock solution (5 mg/mL in PBS) is added to each well and incubated for 5 h.
The medium will removed and 200 µL DMSO is added to each well to dissolve the MTT metabolic product. Then the plate will shaken at 150 rpm for 5 min and the optical density is measured at 560 nm. Untreated cells (basal) are used as a control of viability (100%) and the results will be expressed as % viability (log) relative to the control [24-26].

## RESULTS AND DISCUSSION

**In vitro *release study of cip nanoparticles***

Particles morphology come to a choice of nominal role of particles, spoiling, patterned release of drug from biopolymer multifaceted structure, hauling of particulates in the body, internalization of drug. Transmission electron microscopy was used to image prepared plain and polymeric nanoparticles of CIP, as shown in the FESEM image. The CIP-stuffed biopolymer nanoparticles were prepared as globular plain and polymeric nanoparticles. Hence, all the nano formulation encapsulated in the polymer in circular shape for the basic function of nano formulation, release of CIP and bioenhancers from the polymer matrix, transport of CIP and bioenhancers in the body and internalization of CIP and bio-enhancers by many folds than the free CIP and bio-enhancers (Table 1 and Figures 1-6).

| Concentration (µg/ml) | Absorbance (nm) |
|---|---|
| 0 | 0 |
| 20 | 0.117 |
| 40 | 0.251 |
| 60 | 0.409 |
| 80 | 0.518 |
| 100 | 0.636 |

**Table 1:** Calibration curve of CIP.




**Figure 1:** Calibration curve of CIP in water.




**Figure 2:** Calibration curve of CIP in phosphate buffer pH 7.4.



**Figure 3:** FESEM image of CIP nanoparticles.



**Figure 4:** FESEM image of CIP nanoparticles.



**Figure 5:** FESEM image of CIP nanoparticles.



**Figure 6:** FESEM image of CIP nanoparticles.

**In vitro *anti cancer***

*In Vitro* anti-cancer Activity was performed by gumghatti cisplatin nanoparticles concentrations such as 18.5 µg/ml, 37.5 µg/ml, 75 µg/ml, 150 µg/ml and 300 µg/ml. Standard medication cisplatin antagonistic to tumor were performed among assorted concentrations such as 8.25 µg/ml, 16.25 µg/ml, 33 µg/ml, 66 µg/ml and 100 µg/ml. The anticancer action of gumghatti cisplatin nanoparticles against HepG2 increased while in the centralization of gumghatti cisplatin nanoparticles IC50-(6.438 ± 0.9057) exhibit great outcomes when compared amid standard CIP IC50-(34.52 ± 0.9738). Beforehand, the anticancer movement of gumghatti cisplatin nanoparticles has been considered againt Dalton's Lymphoma Ascite (DLA) cell lines, human laryngeal Hep-2 cell lines and human leukemic monocyte lymphoma individually.

## CONCLUSION

In this current study it is decided that it is possible to prepare the nanoparticles containing cisplatin using gumghatti as polymer by nanoprecipitation method. The *in vitro* release pattern of the prepared nanoparticle was found to be 98.53% in 2 hours. The antitumor activity of the prepared novel nanoformulation containing cisplatin as the drug shows a significant reduction of cell damage so the developed formulation, hence suitable for the better cancer treatment.

## REFERENCES

[1] Wiener H., *J Amer Chem Soc*, **1947**, 69:17-20.
[2] Hosoya H., *Bull Chem Soc* Jpn, **1971**, 44:2332-2337.
[3] Randic M., *J Am Chem Soc*, **1975**, 97:6609-6615.
[4] Balaban AT., *J Chem Inf Comput Sci*, **1985**, 25:334-343.

[5] Kobayashi J., *Cheng J., Walchli MR.*, et al. J Org Chem, **1988**, 53:1800.
[6] Schmitz FJ., *Deguzman FS., Hoseain MB*., et al. J Org Chem, **1991**, 56:804.
[7] Gunawardana *GP., Koehn FE., Lee AY*., et al. J Org Chem, **1992**, 57:1523-1526
[8] Feynman R., *Calif Inst Tech, **1960***, 15:1-24.
[9] Muller RH., *Maassen S., J Cont Release*, **1997**, 47:261-269.
[10] Mukherjee S., *Ray., Thakur RS., et al. Indian J pharm Sci*, **2009**, 71:349-358.
[11] Jumaa M., *Muller BW., Eur J Pharm Sci*, **2000**, 9:285-290.
[12] Bunjes H., *J Pharm Pharmacol*, **2010**, 62:1637-1645.
[13] Harde H., *Expert Opin Drug Del*, **2010**, 8:1407-1424.
[14] Kayser O., Lemke A., Hernandez TN., et al. *Curr Pharm Biotechnol*. **2005**, 6:3-5.
[15] Muller RH., Maeder K., Gohla S., et al. *Eur J Pharm Sci*, **2000**, 50:161-177.
[16] Freitas C., Muller R., *Eur J Pharm Biopharm,* **1999**, 47:125-132.
[17] Ekambaram P., Sathali AB., Priyanka k., et al. *Rev Chem Comm*, **2012**, 2:80-102.
[18] Shah C., Shah V., Upadhyay U., et al. *Curr Pharm Res*, **2011**, 4:351-368.
[19] Loxley A., Drug Delivev Technol, **2009**, 9:8-32.
[20] Müller RH., Radtke M., Wissing SA., et al. *Adv Drug Deliv Rev*, **2002**, 54:131-155.
[21] Pardeshi C., Rajput P., *Acta Pharm,* **2012**, 62:433-472.
[22] Martins S., Sarmento B., *Int J Nanomed*, **2007**, 2:591-595.
[23] Khatak S., Dureja H., *Rec Pat Nanot*, **2015**, 9:150-177.
[24] Geszke MM., Moritz M., *Mater Sci Eng C*, **2016**, 68:982-994.
[25] Kovacevic A., Savic S., *Int J Pharm,* **2011**, 406:163-172.
[26] Mehnert W., Mader K., *Adv Drug Deliv Rev*, **2001**, 47:165-196.